Impact Biomedicines' exit this week for a whopping $7B is the largest since AbbVie's $10B+ acquisition of Stemcentrx in 2016. In all, 14 cancer therapy companies have exited for over $1B since 2014.
Celgene and Boehringer Ingelheim Venture Fund are two standout corporate investors ramping up their cancer therapeutics portfolios.
The retail giant's latest patent details a system for shoppers to see 3D renderings of their fresh items online prior to purchasing them for delivery or pick-up.
Among bulge bracket banks, JPMorgan is making a bigger push into payments technology as digital banking becomes a strategic priority.
Startups developing improved sensor technologies are hot investment and acquisition targets as they compete to supply growing markets in autonomous driving, drones, and beyond.
As it accelerates its activity in non-beer categories, Belgium-based AB InBev is broadening its focus and increasing its global presence in the beverage space.